Moderna (MRNA) Payables: 2017-2025
Historic Payables for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $267.0 million.
- Moderna's Payables fell 28.42% to $267.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 20.81%. This contributed to the annual value of $405.0 million for FY2024, which is 22.12% down from last year.
- Latest data reveals that Moderna reported Payables of $267.0 million as of Q3 2025, which was up 52.57% from $175.0 million recorded in Q2 2025.
- In the past 5 years, Moderna's Payables registered a high of $520.0 million during Q4 2023, and its lowest value of $8.0 million during Q1 2021.
- For the 3-year period, Moderna's Payables averaged around $329.2 million, with its median value being $310.0 million (2023).
- In the last 5 years, Moderna's Payables spiked by 2,387.50% in 2022 and then crashed by 52.96% in 2024.
- Moderna's Payables (Quarterly) stood at $302.0 million in 2021, then spiked by 61.26% to $487.0 million in 2022, then climbed by 6.78% to $520.0 million in 2023, then decreased by 22.12% to $405.0 million in 2024, then declined by 28.42% to $267.0 million in 2025.
- Its last three reported values are $267.0 million in Q3 2025, $175.0 million for Q2 2025, and $226.0 million during Q1 2025.